Showing results (1701-1710 of 1,802) with videos related to

Sort By:
Pageof 181
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Blood Advances|July 10, 2024
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphomaPriyanka A Pophali, Joshua A Fein, Kwang W Ahn, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaDirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patientsMichal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
Neurology|March 17, 2000
Vagus nerve stimulation therapy for epilepsy in older adultsJ I Sirven, M Sperling, D Naritoku, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyG V Long, M S Carlino, C McNeil, et al.
The New England Journal of Medicine|September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanomaPier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
Pageof 181